Koeberl, D., Case, L., Smith, E. C., Li, Y., Walters, C., Hornik, C., … Kishnani, P. S. (2018). Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT. In Molecular Genetics and Metabolism (Vol. 123, pp. S79–S80). Elsevier BV. https://doi.org/10.1016/j.ymgme.2017.12.202

Koeberl, Dwight, Laura Case, Edward C. Smith, Yanzhen Li, Crista Walters, Christoph Hornik, Beth Thurberg, Deeksha Bali, Nenad Bursac, and Priya S. Kishnani. “Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT.” In Molecular Genetics and Metabolism, 123:S79–80. Elsevier BV, 2018. https://doi.org/10.1016/j.ymgme.2017.12.202.

Koeberl D, Case L, Smith EC, Li Y, Walters C, Hornik C, et al. Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT. In: Molecular Genetics and Metabolism. Elsevier BV; 2018. p. S79–80.

Koeberl, Dwight, et al. “Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT.” Molecular Genetics and Metabolism, vol. 123, no. 2, Elsevier BV, 2018, pp. S79–80. Crossref, doi:10.1016/j.ymgme.2017.12.202.

Koeberl D, Case L, Smith EC, Li Y, Walters C, Hornik C, Thurberg B, Bali D, Bursac N, Kishnani PS. Correction of biochemical abnormalities and gene expression associated with improved muscle function in a phase I/II clinical trial of clenbuterol in Pompe disease patients stably treated with ERT. Molecular Genetics and Metabolism. Elsevier BV; 2018. p. S79–S80.